All materials can be found in full at the links provided.
Key Resources (listed chronologically, beginning with the most recent)
“Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices.” I-MAK. August 2, 2018. Available at http://allh.us/gwqR.
“The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation.” Grabowski, H., DiMasi, J., and Long, G. Health Affairs. February 2015. Available at http://allh.us/nFCT.
Additional Resources (listed chronologically, beginning with the most recent)
“IP Explained: Myth vs. Fact about Strong Patent Protections in the Biopharmaceutical Industry.” Wilbur, T. Pharmaceutical Research and Manufacturers of America. The Catalyst. May 2, 2019. Available at http://allh.us/Bd9M.
“FDA Approves More Generic Drugs, but Competition Still Lags.” The Pew Charitable Trusts. February 25, 2019. Available at http://allh.us/VauM.
“May Your Drug Price Be Evergreen.” Feldman, R. Journal of Law and the Biosciences. December 7, 2018. Available at http://allh.us/haun.
“Balancing Innovation and Competition in the Biologics Marketplace.” Korn, D. Pharmaceutical Research and Manufacturers of America. The Catalyst. October 11, 2018. Available at http://allh.us/HCrk.
“Patent Policy Prescriptions.” I-MAK. October, 9, 2018. Available at http://allh.us/GfmD.
“Patentability Standards for Follow-On Pharmaceutical Innovation.” Holman, C., Minssen, T., and Solovy, E. Biotechnology Law Report. June 1, 2018. Available at http://allh.us/fA8v.
“Promoting Competition to Address Pharmaceutical Prices.” Darrow, J. and Kesselheim, A. Health Affairs. March 15, 2018. Available at http://allh.us/vCJQ.
“Health Policy Brief: Patent Settlements.” McCaughan, M. July 21, 2017. Health Affairs. Available at http://allh.us/fyEM.
“Getting to the Root of High Prescription Drug Prices Drivers and Potential Solutions.” Waxman, H., Corr, B., Martin, K., et al. The Commonwealth Fund. July 2017. Available at http://allh.us/9vu4.
“Rising Costs for Patented Drugs Drive Growth of Pharmaceutical Spending in the U.S.” Blue Cross Blue Shield. The Health of America Report. May 3, 2017. Available at http://allh.us/gCTk.
“Enabling Competition in Pharmaceutical Markets.” Morton, F. and Boller, L. Hutchins Center Working Papers No. 30. May 2017. Available at http://allh.us/pfDx.
“A Prescription for Excessive Drug Pricing: Leveraging Government Patent Use for Health.” Brennan, H., Kapczynski, A., Monahan, C., et al. Yale Journal of Law Technology. 2017. Available at http://allh.us/eNPT.
“How Patent Law Can Block Even Lifesaving Drugs.” Frakt, A. The New York Times. September 28, 2015. Available at http://allh.us/rMta.
“The Importance of Patents to Innovation: Updated Cross-Industry Comparisons with Biopharmaceuticals.” Cockburn I. and Long G. Journal Expert Opinion on Therapeutic Patents. July 2015. Available at http://allh.us/Yg8J.
“Intellectual Property Underpinnings of Pharmaceutical Innovation: A Primer.” Rinehart, W. American Action Forum. July 29, 2014. Available at http://allh.us/Tujd.
“Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007.” Conti, R.M. and Ernst, B.R. National Bureau of Economic Research. March 2014. Available at http://allh.us/Rg7u.
“Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions.” Federal Trade Commission. July 2010. Available at http://allh.us/cdfH